I期临床-话题@MedSci

#I期临床#

570篇内容 | 7009人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653236, encodeId=b9541653236e8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, objectType=article, longId=299177, objectId=355f2991e79c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=355f2991e79c, replyNumber=0, likeNumber=96, createdTime=2022-02-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=355f2991e79c, moduleTitle=FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=355f2991e79c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653178, encodeId=554a16531e823, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%, objectType=article, longId=210412, objectId=3592210412ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3592210412ef, replyNumber=0, likeNumber=86, createdTime=2022-03-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3592210412ef, moduleTitle=NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3592210412ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653204, encodeId=bce1165320442, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=75, createdTime=2021-09-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653235, encodeId=7982165323524, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验, objectType=article, longId=299008, objectId=40752990089a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40752990089a, replyNumber=0, likeNumber=0, createdTime=2022-06-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40752990089a, moduleTitle=南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40752990089a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653210, encodeId=736216532108e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=59, createdTime=2022-06-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653170, encodeId=8a0416531e001, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, objectType=article, longId=209081, objectId=08c1209081f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08c1209081f4, replyNumber=0, likeNumber=63, createdTime=2022-01-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08c1209081f4, moduleTitle=ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08c1209081f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653193, encodeId=16831653193f2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, objectType=article, longId=213384, objectId=18202133844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18202133844d, replyNumber=0, likeNumber=69, createdTime=2021-07-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18202133844d, moduleTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18202133844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653209, encodeId=7eb01653209ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, objectType=article, longId=217668, objectId=1fca21e668fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca21e668fc, replyNumber=0, likeNumber=65, createdTime=2022-02-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca21e668fc, moduleTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca21e668fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653228, encodeId=fb49165322812, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, objectType=article, longId=265037, objectId=970226503ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970226503ec6, replyNumber=0, likeNumber=114, createdTime=2022-02-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970226503ec6, moduleTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970226503ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653180, encodeId=6cc1165318043, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, objectType=article, longId=210523, objectId=496421052350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=496421052350, replyNumber=0, likeNumber=68, createdTime=2021-07-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=496421052350, moduleTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=496421052350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653194, encodeId=1be41653194b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功, objectType=article, longId=213850, objectId=35db213850ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35db213850ab, replyNumber=0, likeNumber=73, createdTime=2021-08-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35db213850ab, moduleTitle=JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35db213850ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653188, encodeId=8fef16531886b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, objectType=article, longId=212072, objectId=e36e2120e2eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e36e2120e2eb, replyNumber=0, likeNumber=61, createdTime=2021-07-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e36e2120e2eb, moduleTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e36e2120e2eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653182, encodeId=2016165318244, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, objectType=article, longId=210971, objectId=aae42109e1a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae42109e1a9, replyNumber=0, likeNumber=0, createdTime=2021-12-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae42109e1a9, moduleTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae42109e1a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653218, encodeId=bada1653218ec, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败, objectType=article, longId=219618, objectId=26792196183f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26792196183f, replyNumber=0, likeNumber=104, createdTime=2022-09-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26792196183f, moduleTitle=NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26792196183f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653185, encodeId=19c01653185ce, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Sci Trans Med：Tau抗体semorinemab I期临床安全, objectType=article, longId=211480, objectId=b1742114801f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1742114801f, replyNumber=0, likeNumber=69, createdTime=2021-12-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1742114801f, moduleTitle=Sci Trans Med：Tau抗体semorinemab I期临床安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1742114801f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653213, encodeId=529c1653213c0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=68, createdTime=2022-02-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653205, encodeId=166a1653205ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, objectType=article, longId=216995, objectId=8c02216995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c02216995b9, replyNumber=0, likeNumber=62, createdTime=2022-01-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c02216995b9, moduleTitle=2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c02216995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653192, encodeId=b599165319284, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, objectType=article, longId=213343, objectId=818f213343eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818f213343eb, replyNumber=0, likeNumber=73, createdTime=2021-09-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818f213343eb, moduleTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818f213343eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653214, encodeId=dd7a165321463, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, objectType=article, longId=218737, objectId=eb23218e37f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb23218e37f3, replyNumber=0, likeNumber=84, createdTime=2021-12-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb23218e37f3, moduleTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb23218e37f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653164, encodeId=0774165316416, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, objectType=article, longId=207800, objectId=df3320e8001b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3320e8001b, replyNumber=0, likeNumber=0, createdTime=2021-12-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3320e8001b, moduleTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3320e8001b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA暂停了苯丙酮尿症（PKU）基因疗法BMN 307的I/II期临床试验

2022-02-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：单剂量Ad26.COV2.S疫苗III期临床效果喜人，对南非变异株的预防效果超过50%

2022-03-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-09-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

南京传奇生物已暂停CAR-T疗法LB1901的I期临床试验

2022-06-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2022-06-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ZYESAMI治疗COVID-19呼吸衰竭，IIb / III期临床试验取得积极结果

2022-01-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新

2021-07-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床

2022-02-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN

2022-02-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功

2021-07-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAMA Psychiatry：Zuranolone治疗产后抑郁III期临床获得成功

2021-08-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究

2021-07-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点

2021-12-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败

2022-09-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Sci Trans Med：Tau抗体semorinemab I期临床安全

2021-12-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2022-02-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2021年9月12日简报：云南新增本土确诊病例7例、福建莆田市累计发现6例确诊；第二代新冠疫苗已完成II期临床试验；66岁女科学家因mRNA疫苗获大奖

2022-01-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C

2021-09-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动

2021-12-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

2021-12-12

科室
- - 订阅+
  - 更多科室
工具
服务